Press release

Masimo Announces Reinstatement of Import Ban on Infringing Apple Watches

IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI), a global leader in innovative noninvasive monitoring technologies, welcomes the Federal Circuit’s

articleMasimo CorporationJanuary 17, 20245/company/masimo-corporation/news/masimo-announces-reinstatement-of-import-ban-on-infringing-apple-watches-2024-01-17
Masimo Announces Reinstatement of Import Ban on Infringing Apple Watches

About this update from Masimo Corporation

[{"type":"text","content":" IRVINE, Calif.--(BUSINESS WIRE)--\nMasimo (NASDAQ: MASI), a global leader in innovative noninvasive monitoring technologies, welcomes the Federal Circuit’s ruling to lift the temporary stay on the import ban of certain Apple Watch models. This decision reinstates the U.S. International Trade Commission’s import ban and cease and desist order on Apple watches that were found to infringe Masimo’s patented pulse oximetry technology.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240117431473/en/Masimo W1® (Photo: Business Wire)\n“The Federal Circuit's decision to lift the temporary stay is a victory for the integrity of the American patent system and the safety of people relying on pulse oximetry,” said Joe Kiani, Founder and CEO of Masimo. “It affirms that even the largest and most powerful companies must respect the intellectual rights of American inventors and must deal with the consequences when they are caught infringing others’ patents.”\n\n\nMasimo has previously made available a study showing that Apple Watch’s pulse oximetry missed over 90% of potentially life-threatening events. The Apple Watch pulse oximeter was not cleared by the United Stated Food and Drug Administration for medical use. On the other hand, the Masimo W1® health watch was recently cleared by the FDA for its indicated medical uses, including continuous pulse oximetry. Masimo’s pulse oximetry technology is used on over 200 million patients in hospitals a year1 and has been proven to help save babies’ eyesight in the neonatal ICU,2 detect critical congenital heart defects in newborns,3 and save the lives of patients in post-surgical wards who are taking opioids.4-7\n\n\n@Masimo | #Masimo\n\n\nAbout Masimo\n\n\nMasimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 i...

More updates from Masimo Corporation